Zacks Investment Research
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseResMed is expected to report Q3 2026 earnings of $2.67 per share (up 4.7% YoY) with revenues of $1.39 billion (up 4% YoY) on October 29. However, the company's Earnings ESP is -0.60%, indicating recent analyst pessimism, combined with a Zacks Rank #3, making it difficult to predict an earnings beat. Despite a strong historical track record of beating estimates, ResMed does not appear to be a compelling earnings-beat candidate.